Alzheimer’s disease (AD) is a growing global health concern, but current drug therapies have shown limited effectiveness for symptom management and disease modification. Medium chain triglycerides (MCTs) have emerged as a potential nutritional therapy, but evidence remains inconclusive. Key Facts: MCTs may provide an alternative brain fuel source and reduce AD biomarkers like amyloid-beta. Small …
A new drug recently approved for Alzheimer’s disease aims to treat the underlying cause of the condition by removing amyloid plaques in the brain. Though promising, the drug called aducanumab also comes with potential side effects that require careful monitoring. Key facts: Aducanumab is the first drug that targets and removes amyloid plaques, sticky buildups …
Researchers have uncovered an important new mechanism that causes inflammation and damage to the brain’s white matter in Alzheimer’s disease. This discovery about how brain cells called microglia die could lead to new Alzheimer’s treatments. Key Facts: The study found that microglia, which are immune cells in the brain, die through a process called “ferroptosis” …
A new large genetics study has discovered new clues into how levels of a protein called apolipoprotein E (ApoE) in the blood may influence a person’s risk of developing Alzheimer’s disease. Key facts: Researchers found 9 new genetic variants that influence ApoE levels in the blood. Some raise levels, while others lower levels. People with …
Summary: A new study reveals how certain genes and education levels impact Alzheimer’s disease risk, even in individuals destined to develop dementia. Key facts: The APOE gene influences Alzheimer’s onset in people with a genetic mutation causing early-onset Alzheimer’s. Having APOE e4 accelerates onset of decline while APOE e2 delays it. More years of education …
